HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Toxicity, second cancers cause researchers to question radiation’s role in Hodgkin lymphoma
• Symposium findings provide ‘wake-up call’ about postoperative complications, registry discrepancies Nicholas J. Petrelli, MD, FACS
• Alcohol and cancer risk: What is the connection?
• ASCO names new CEO
• Association of Community Cancer Centers names new president
• Bladder cancer institute awards $500,000 worth of research grants
• Dana-Farber Cancer Institute names new president, CEO
• GW Cancer Center appoints associate director for patient-centered initiatives
• Lewis C. Cantley, PhD, receives Wolf Prize in Medicine
• Pediatric Blood and Marrow Transplant Consortium presents lifetime achievement award
• Society of Gynecologic Oncology appoints new CEO
• The University of Texas MD Anderson Cancer Center honors faculty
• Pancreatic Cancer Drugs in the Pipeline
• Propensity matching and the GIGO principle Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA approves Kovaltry for hemophilia A
• FDA approves Xalkori to treat ROS1-positive NSCLC
• FDA grants orphan drug designation to BPX-501 for GVHD, immunodeficiency after stem cell transplants
• FDA grants orphan drug designation to WT1 cancer vaccine for malignant pleural mesothelioma
• FDA grants priority review to MPDL3280A for treatment of advanced, metastatic urothelial carcinoma
• FDA reports increase of adverse events with Zydelig, six trials stopped
• A 57-year-old woman with an anterior mediastinal mass of unusual histology Munir Ghesani, MD, FACNM; Ajit Karakbelkar, MD
• ASCO: Expanded genetic testing should be standard for metastatic colorectal cancer
• Circulating histones may predict thrombocytopenia severity in ICU patients
• Clonal abnormalities may serve as diagnostic tool for blood cancers
• Combination therapy may extend OS in metastatic pancreatic cancer
• Common genetic variants linked to high VTE incidence in black patients
• CYP3A7 allele predicts poor outcomes for lung and breast cancer, leukemia
• ED interventions reduce time to treatment of febrile neutropenia
• Experts reveal ‘troubling’ industry-employed strategies to delay availability of generic cancer drugs
• Financial burden linked to depression in cancer survivors
• Gemtuzumab ozogamicin response linked to CD33 expression level in pediatric AML
• Hospitalization for heart failure may predict VTE risk
• HSCT may improve DFS, OS in older patients with AML
• Imetelstat demonstrates safety, efficacy for essential thrombocythemia
• Intensive, multi-agent regimen may prolong EFS in metastatic rhabdomyosarcoma
• Most patients with advanced cancer want genetic testing results
• Neoadjuvant chemotherapy demonstrates favorable outcomes in pediatric germ cell tumors
• Poor, minority AYAs less likely to survive Hodgkin’s lymphoma
• Poor OS observed in men with brain metastases from germ cell tumors
• PSA testing rates differ among urologists, PCPs
• RAS/MAPK hyperactivation may predict worse outcomes in undifferentiated pleomorphic sarcomas
• Ropeginterferon alfa 2b shows promise for polycythemia vera
• Routine CT scans after SBRT effectively detect NSCLC progression
• Shorter bleomycin regimen demonstrates acceptable toxicity profile in older patients with Hodgkin lymphoma
• Trial availability, patient eligibility barriers to enrollment onto genomically matched trials
• Tumor-treating fields prolong PFS, OS in glioblastoma
• USPSTF: Insufficient evidence exists for anemia testing, iron supplementation in pregnant women
• Benefits, harms of routine skin cancer screening uncertain
• Bone density scans underutilized after prophylactic oophorectomy
• Brain may become ‘just another organ’ in treatment of metastatic melanoma
• Clinical trials ‘remain the priority’ for patients with uveal melanoma
• Endometrial cancers with high microsatellite instability may benefit from immunotherapy
• Experts debate role of completion lymphadenectomy for node-positive melanoma
• ‘Explosion of genomic data’ should improve treatment of cutaneous T-cell lymphoma
• Extent of thyroid surgery often miscoded in cancer registries
• Gene mutations extend PFS, OS in ovarian cancer
• Hospital adherence to quality metrics may not improve colon cancer outcomes
• Insulin may increase mammographic density in women with diabetes
• Ipilimumab, interferon debated as standard adjuvant therapy for high-risk disease
• Mastectomy improves survival in younger, BRCA-positive women with ovarian cancer
• Multiple gene mutations may predict recurrence in malignant melanoma
• Oncogene expression may guide treatment, predict outcomes in head, neck cancer
• Patients with head and neck cancer often resort to cost-coping strategies
• Pembrolizumab shows early promise in repair-deficient endometrial cancer
• Physical activity does not impact mammographic density
• Sonidegib offers long-term disease control in basal cell carcinoma
• Updates in staging, management may benefit future of Merkel cell carcinoma treatment
• The potential of reversal agents for target-specific oral anticoagulants Amanda M. Morrill, PharmD, BCPS; Kristine C. Willett, PharmD, FASHP